Proven Therapy Assurance
Key clinical outcomes for Entrant™ ICD solutions include:
98.4% of patients did not receive inappropriate shocks in REDUCE-IT study (CI:97.2-99.2, p<0.0001)1
>800 patients annually with challenging arrhythmias could have their lives saved because of VF Therapy Assurance2
This device is commercially available for use in select international markets.
References
- Veltmann C, Wöhrle A, Busch M, et al. Reduction of inappropriate shocks of ICDs with enhanced SVT discriminators. EUROPACE presentation; 2017.
- Data on file. 60101422 Internal Validation Report. Total 2019 global high-voltage implants, all manufacturers, estimated to be 440,434 units (Source: Abbott Market Research).
MAT-2009197 v2.0